Microglia, Not Plaques, Cause Alzheimer’s Sleep Loss, Study Finds

<>

Researchers at the University of Kentucky have identified that immune cells called microglia, rather than amyloid plaques, drive sleep disruption in Alzheimer’s disease. By using the drug Pexidartinib to temporarily deplete these cells in animal models, the team successfully restored two hours of daily sleep, offering a potential new therapeutic target.

In Plain English: The Clinical Takeaway

• In Alzheimer’s, they overreact to amyloid plaques, causing inflammation that disrupts sleep cycles like a fire sprinkler flooding a house.
• Restoring Rhythm: By temporarily blocking these overactive immune cells with a specific inhibitor, researchers restored two hours of sleep in study subjects.
• A Shift in Focus: This research suggests that targeting the brain’s inflammatory immune response, rather than just clearing protein plaques, may be critical to managing cognitive decline.

Microglia: The Hidden Drivers of Sleep Fragmentation

For decades, the medical community has operated under the assumption that the physical accumulation of amyloid plaques—sticky protein clumps—was the primary culprit behind the cognitive decline and sleep disturbances observed in Alzheimer’s disease. However, a study published in the journal Alzheimer’s & Dementia (2026) challenges this paradigm. Led by Dr. Shannon L. Constantino at the University of Kentucky, the research demonstrates that the brain’s “resident immune system” is the primary driver of sleep loss.

The study utilized light sheet microscopy to visualize brain tissue in 3D, allowing researchers to observe how microglia interact with the environment. When these cells detect amyloid plaques, they initiate an inflammatory cascade. Dr. Macauley described this process as the immune cells “partying all night,” effectively keeping the brain in a state of hyper-arousal that prevents restorative rest. This suggests that the sleep loss associated with Alzheimer’s is not merely a symptom of neuronal damage, but an active, immune-mediated process.

Clinical Methodology and Experimental Evidence

To confirm this mechanism, the researchers utilized Pexidartinib (PLX3397), a drug originally developed for oncology research that inhibits the Colony Stimulating Factor 1 Receptor (CSF1R). This pathway is essential for microglial survival. By administering the drug to mice models over a 14-day period, the team achieved an 87% reduction in brain microglia. The result was a significant improvement in sleep architecture, with subjects regaining over two hours of sleep per day.

The study employed advanced electroencephalography (EEG) and electromyography (EMG) to track electrical brain activity and muscle movement. This allowed the team to differentiate between various sleep states, including deep restorative sleep and REM (dreaming) sleep, providing a high-resolution view of how the removal of immune cells impacted the brain’s electrical “fingerprint.”

Summary of Microglial Depletion Impact

Metric	Observation
Targeted Mechanism	CSF1R Signaling Pathway
Microglial Reduction	~87% (via Pexidartinib)
Sleep Improvement	+2 Hours/Day
Primary Driver	Immune-mediated inflammation

Regulatory Landscape and Future Implications

While these findings represent a “paradigm shifting” development in neurobiology, clinical application remains distant. Pexidartinib is currently FDA-approved for the treatment of symptomatic tenosynovial giant cell tumor, a rare condition, and carries a “black box” warning for potential hepatotoxicity (liver damage). The transition from animal models to human clinical trials requires rigorous evaluation of whether the benefits of suppressing microglial activity outweigh the systemic risks of immune modulation.

Photo: sciencedaily.com

Contraindications & When to Consult a Doctor

References

• Macauley, S.L., et al. (2026). “Microglia-mediated neuroinflammation as a driver of sleep fragmentation in Alzheimer’s disease.” Alzheimer’s & Dementia.
• FDA Drug Database: Pexidartinib (Turalio) prescribing information and safety warnings.